Limertinib in Patients With Locally Advanced or Metastatic EGFR T790M–Mutated NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study
J Thorac Oncol 2022 Jun 02;[EPub Ahead of Print], Y Shi, B Li, L Wu, Y Pan, Z Pan, Y Liu, Y Fan, Y Ji, J Fang, Q Shi, J Shi, H Gao, Y Hu, X Wang, Z He, R Ma, Y Zhang, D Jiang, Y Bai, Y Zhang, L Huang, T Zhou, H Liu, D Wang, Q Wen, G Chen, A Zang, X Wang, X Zhang, J Hu, R Yang, G Zhang, K Gu, L Wang, Q Wang, Z Wei, Z Li, H Lu, H Zhang, H Chen, T SongFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.